Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15484949 | 0.82 | ALDH1A1 (0.37) | FDFT1ALDH1A1TSHRTHRB | |
| SCHEMBL15484688 | 0.82 | ALDH1A1 (0.37) | FDFT1ALDH1A1TSHRTHRB | |
| SCHEMBL5179014 | 0.78 | — | — | |
| SCHEMBL20535312 | 0.74 | — | — | |
| SCHEMBL239490 | 0.74 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL22575455 | 0.73 | PAOX (0.35) | FDFT1 | |
| Bromide SCHEMBL30398337 | 0.73 | PAOX (0.35) | FDFT1 | |
| SCHEMBL15741252 | 0.72 | KDM4E (0.33) | ALDH1A1TSHRTHRB | |
| Hydrochloric Acid SCHEMBL1965268 | 0.71 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| SCHEMBL12911823 | 0.71 | TSHR (0.46) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | FDFT1 2011/4885ALDH1A1 1288/4885TSHR 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.